ES2597835T3 - Proteína asociada a enfermedad - Google Patents

Proteína asociada a enfermedad Download PDF

Info

Publication number
ES2597835T3
ES2597835T3 ES02737923.9T ES02737923T ES2597835T3 ES 2597835 T3 ES2597835 T3 ES 2597835T3 ES 02737923 T ES02737923 T ES 02737923T ES 2597835 T3 ES2597835 T3 ES 2597835T3
Authority
ES
Spain
Prior art keywords
gene
cells
nucleic acid
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02737923.9T
Other languages
English (en)
Spanish (es)
Inventor
Thierry Leveillard
Saddek Mohand-Said
David Hicks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Universite de Strasbourg
Original Assignee
Novartis AG
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Universite de Strasbourg filed Critical Novartis AG
Application granted granted Critical
Publication of ES2597835T3 publication Critical patent/ES2597835T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES02737923.9T 2001-04-06 2002-04-05 Proteína asociada a enfermedad Expired - Lifetime ES2597835T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0104712 2001-04-06
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications
PCT/EP2002/003810 WO2002081513A2 (en) 2001-04-06 2002-04-05 Disease-associated protein

Publications (1)

Publication Number Publication Date
ES2597835T3 true ES2597835T3 (es) 2017-01-23

Family

ID=8862037

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02737923.9T Expired - Lifetime ES2597835T3 (es) 2001-04-06 2002-04-05 Proteína asociada a enfermedad

Country Status (22)

Country Link
US (6) US7795387B2 (enExample)
EP (1) EP1379657B1 (enExample)
JP (2) JP4370428B2 (enExample)
KR (1) KR100913258B1 (enExample)
CN (1) CN1529753B (enExample)
AU (1) AU2002312794B8 (enExample)
BR (1) BRPI0208870B8 (enExample)
CA (1) CA2443345C (enExample)
CZ (1) CZ305800B6 (enExample)
EC (1) ECSP024345A (enExample)
ES (1) ES2597835T3 (enExample)
FR (1) FR2823221B1 (enExample)
HU (1) HU226307B1 (enExample)
IL (3) IL158013A0 (enExample)
MX (1) MXPA03009114A (enExample)
NO (1) NO331277B1 (enExample)
NZ (1) NZ528376A (enExample)
PL (1) PL213658B1 (enExample)
RU (1) RU2384586C2 (enExample)
SK (1) SK288465B6 (enExample)
WO (1) WO2002081513A2 (enExample)
ZA (1) ZA200307403B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
PT1625210E (pt) 2003-05-21 2011-03-15 Genzyme Corp Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
WO2009146183A1 (en) * 2008-04-15 2009-12-03 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
WO2010029130A1 (en) * 2008-09-10 2010-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal viability factor and use thereof
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
DK2797613T3 (da) 2011-10-27 2020-03-02 Wellstat Ophthalmics Corp Vektorer, der koder for rod-derived cone viability-faktor
US20150038557A1 (en) 2012-02-24 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treatment of retinal degenerative diseases
WO2014060517A1 (en) * 2012-10-17 2014-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (amd)
PL3412684T3 (pl) 2013-07-31 2022-08-08 Novartis Ag Nowe wektory selekcyjne i sposoby selekcji eukariotycznych komórek gospodarzy
JP6684343B2 (ja) 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
WO2017120294A1 (en) 2016-01-05 2017-07-13 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
US10946063B2 (en) 2016-10-11 2021-03-16 Welltat Ophthalmics Corporation Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide
JP7495756B2 (ja) * 2019-12-09 2024-06-05 北京中因科技有限公司 医薬の製造におけるＣＹＰ４Ｖ２およびＲｄＣＶＦの使用
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
US20250276088A1 (en) * 2021-07-07 2025-09-04 Institut National de la Santé et de la Recherche Médicale Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
WO2024206928A1 (en) 2023-03-30 2024-10-03 Pharma Cinq, Llc VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2010029130A1 (en) 2008-09-10 2010-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal viability factor and use thereof

Also Published As

Publication number Publication date
NO331277B1 (no) 2011-11-14
MXPA03009114A (es) 2004-11-22
US20130287738A1 (en) 2013-10-31
AU2002312794B8 (en) 2006-01-12
ECSP024345A (es) 2004-06-28
CZ305800B6 (cs) 2016-03-23
PL213658B1 (pl) 2013-04-30
WO2002081513A3 (en) 2003-05-01
US8114849B2 (en) 2012-02-14
RU2003130638A (ru) 2005-04-20
FR2823221B1 (fr) 2004-04-02
SK12232003A3 (sk) 2004-03-02
US7795387B2 (en) 2010-09-14
US8518695B2 (en) 2013-08-27
NO20034452L (no) 2003-12-04
US8394756B2 (en) 2013-03-12
CA2443345C (en) 2012-12-04
CN1529753A (zh) 2004-09-15
WO2002081513A2 (en) 2002-10-17
US20120108657A1 (en) 2012-05-03
US8957043B2 (en) 2015-02-17
BR0208870A (pt) 2004-04-27
CZ20032706A3 (cs) 2003-12-17
US20120108523A1 (en) 2012-05-03
NO20034452D0 (no) 2003-10-03
ZA200307403B (en) 2004-04-21
HUP0303730A2 (en) 2006-02-28
KR20030094317A (ko) 2003-12-11
JP4571695B2 (ja) 2010-10-27
IL199316A (en) 2011-01-31
US20090062188A1 (en) 2009-03-05
EP1379657B1 (en) 2016-08-17
SK288465B6 (sk) 2017-06-02
BRPI0208870B1 (pt) 2016-01-12
HU226307B1 (en) 2008-08-28
NZ528376A (en) 2005-09-30
JP4370428B2 (ja) 2009-11-25
AU2002312794B2 (en) 2005-12-01
CA2443345A1 (en) 2002-10-17
RU2384586C2 (ru) 2010-03-20
US8071745B2 (en) 2011-12-06
CN1529753B (zh) 2013-06-12
EP1379657A2 (en) 2004-01-14
BRPI0208870B8 (pt) 2021-05-25
US20080004231A1 (en) 2008-01-03
IL158013A0 (en) 2004-03-28
US20040204350A1 (en) 2004-10-14
PL364681A1 (en) 2004-12-13
JP2009232843A (ja) 2009-10-15
KR100913258B1 (ko) 2009-08-21
IL158013A (en) 2010-12-30
FR2823221A1 (fr) 2002-10-11
JP2005502319A (ja) 2005-01-27

Similar Documents

Publication Publication Date Title
ES2597835T3 (es) Proteína asociada a enfermedad
ES2281529T3 (es) Peptidos eficaces en el tratamiento de tumores y otras afecciones que requieren la eliminacion o destruccion de celulas.
ES2287952T3 (es) Proteinas de trebol intestinal.
ES2284502T3 (es) 22025, una nueva nucleotido ciclico fosfodiesterasa humana.
US9353162B2 (en) Disease-associated proteins
AU2002312794A1 (en) Disease-associated protein
JP2004516024A (ja) Ｃｄ８３発現に影響を及ぼす化合物、前記化合物を含む薬剤組成物及び前記化合物を同定する方法
US6664229B2 (en) Methods for treatment using novel ligands of the neuropeptide receptor HFGAN72
US20030144236A1 (en) Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
ES2359233T3 (es) Proteínas homólogas de la quinasa mnk implicadas en la regulación de la homeostasis energética y en el metabolismo organular.
JPH11255648A (ja) 血管新生阻害剤